Skip Navigation LinksHome > February 2013 - Volume 25 - Issue 1 > Current World Literature
Text sizing:
A
A
A
Current Opinion in Obstetrics & Gynecology:
doi: 10.1097/GCO.0b013e32835cc6b6
CURRENT WORLD LITERATURE: Bibliography

Current World Literature

Free Access

This bibliography is compiled by clinicians from the relevant journals scanned by this publication. It is based on the literature regularly pulled into our database from OvidSP (articles are generally added to the database about two and a half months after publication). In addition, the bibliography contains every paper annotated by reviewers; these references were obtained from a variety of bibliographic databases and published between the beginning of the review period and the time of going to press. The bibliography has been grouped into topics that relate to the reviews in this issue.

▪ Papers considered by the reviewers to be of special interest

▪▪ Papers considered by the reviewers to be of outstanding interest

The number in square brackets following a selected paper, e.g. [7], refers to its number in the annotated references of the corresponding review.

Back to Top | Article Outline
Gynecologic cancer
Research and clinical applications of cancer genome sequencing

Review: (pp. 3–10)

Alley WR, Vasseur JA, Goetz JA, Syoboda M, et al. N-linked Glycan Structures and Their Expressions Change in the Blood Sera of Ovarian Cancer Patients. J Proteome Res 2012; 11:2282–2300.

Bast RC, Skates S, Lokshin A, Moore RG. Differential Diagnosis of a Pelvic Mass Improved Algorithms and Novel Biomarkers. Int J Gynecol Cancer 2012; 22:S5–S8. View Full Text | PubMed | CrossRef

Ben-Hamo R, Efroni S. Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol 2012; 6:3.

Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011; 60:975–984. PubMed | CrossRef

Callesen AK, Mogensen O, Jensen AK, Kruse TA, et al. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. J Proteomics 2012; 75:2758–2772. PubMed | CrossRef

Carser JE, Quinn JE, Michie CO, O'Brien EJ, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 2011; 123:492–498. PubMed | CrossRef

Chambers SK, Martinez JD. The significance of p53 isoform expression in serous ovarian cancer. Future Oncol 2012; 8:683–686. View Full Text | PubMed | CrossRef

Clarke CH, Yip C, Badgwell D, Fung ET, et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011; 122:548–553. PubMed | CrossRef

▪▪. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43: 663–667. [08]

Coticchia CM, Curatolo AS, Zurakowski D, Yang J, et al. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol 2011; 123:295–300. PubMed | CrossRef

Coward J, Kulbe H, Chakravarty P, Leader D, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17:6083–6096.

Dai W, Teodoridis JM, Zeller C, Graham J, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011; 17:4052–4062.

Diaz JP, Gemignani ML, Pandit-Taskar N, Park KJ, et al. Sentinel lymph node biopsy in the management of early-stage cervical carcinoma. Gynecol Oncol 2011; 120:347–352. PubMed | CrossRef

Dorn J, Magdolen V, Gkazepis A, Gerte T, et al. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. Ann Oncol 2011; 22:1783–1790. View Full Text | PubMed | CrossRef

Elschenbroich S, Ignatchenko V, Clarke B, Kalloger SE, et al. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res 2011; 10:2286–2299. PubMed | CrossRef

Fan L, Zhang W, Yin M, Zhang T, et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol 2012; 51:473–479. PubMed | CrossRef

Ferrero A, Dompe D, Ravarino N, Ramella A, et al. Angiogenesis and molecular markers in advanced epithelial ovarian cancer: A retrospective study. Gynecol Oncol 2011; 123:301–307. PubMed | CrossRef

Fischer E, Grunberg J, Cohrs S, Hohn A, et al. L1-CAM-targeted antibody therapy and 177Lu-radioimmunotherapy of disseminated ovarian cancer. Int J Cancer 2012; 130:2715–2721. PubMed | CrossRef

Gaitskell K, Martinek I, Bryant A, Kehoe S, et al. Angiogenesis inhibitors for the treatment of ovarian cancer - art. no. CD007930. Cochrane Database Syst Rev 2011;7930.

Ganapathy E, Su F, Meriwether D, Devarajan A, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer 2012; 130:1071–1081. PubMed | CrossRef

Gloss BS, Patterson KI, Barton CA, Gonzalez M, et al. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers. Cancer Lett 2012; 318:76–85. PubMed | CrossRef

Haldar K, Gaitskell K, Bryant A, Nicum S, et al. Epidermal growth factor receptor blockers for the treatment of ovarian cancer - art. no. CD007927. Cochrane Database Syst Rev 2011;7927.

Hogdall C, Fung ET, Christensen IJ, Nedergaard L, et al. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011; 123:308–313. PubMed | CrossRef

Hua S, An HJ, Ozcan S, Ro GS, et al. Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst 2011; 136:3663–3671. PubMed | CrossRef

Jacobs I, Menon U. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res (Phila Pa) 2011; 4:299–302.

Kaur M, MacPherson CR, Schmeier S, Narasimhan K, et al. In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer. BMC Syst Biol 2011; 5:144.

Kim H, Kim K, No JH, Jeon YT, et al. Prognostic Value of Biomarkers Related to Drug Resistance in Patients with Advanced Epithelial Ovarian Cancer. Anticancer Res 2012; 32:589–594. PubMed

Kim HS, Suh DH, Kim MK, Chung HH, et al. Systematic Lymphadenectomy for Survival in Patients with Endometrial Cancer: A Meta-analysis. Jpn J Clin Oncol 2012; 42:405–412. View Full Text | PubMed | CrossRef

Kim YW, Bae SM, Kim IW, Liu HB, et al. Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. Oncol Rep 2012; 28:585–591. PubMed

Kitajima K, Suzuki K, Senda M, Kita M, et al. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? Annals of Nuclear Medicine 2011; 25:511–519.

Konstantinopoulos PA, Awtrey CS. Management of Ovarian Cancer A 75-Year-Old Woman Who Has Completed Treatment. JAMA-J Am Med Assoc 2012; 307:1420–1429. View Full Text | PubMed | CrossRef

▪. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol 2012; 25:1055–1068. [06]

Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S. microRNA and the pathogenesis of ovarian cancer - a new horizon for molecular diagnostics and treatment? Clin Chem Lab Med 2012; 50:601–615.

▪▪. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012; 104:1503–1513. [10]

Lee JM, Han JJ, Altwerger G, Kohn EC. Proteomics and biomarkers in clinical trials for drug development. J Proteomics 2011; 74:2632–2641. PubMed | CrossRef

Li H, Bitler BG, Vathipadiekal V, Maradeo ME, et al. ALDH1A1 Is a Novel EZH2 Target Gene in Epithelial Ovarian Cancer Identified by Genome-Wide Approaches. Cancer Prev Res (Phila Pa) 2012; 5:484–491.

Liu J, Matulonis UA. Anti-angiogenic Agents in Ovarian Cancer: Dawn of a New Era? Curr Oncol Rep 2011; 13:450–458.

Lokshin AE. The Quest for Ovarian Cancer Screening Biomarkers Are We on the Right Road? Int J Gynecol Cancer 2012; 22:S35–S40.

Lu D, Kuhn E, Bristow RE, Giuntoli RL, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 2011; 122:560–566. PubMed | CrossRef

Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila Pa) 2011; 4:303–306.

Mirandola LJ, Cannon M, Cobos E, Bernardini G, et al. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 2011; 30:127–137. PubMed | CrossRef

Moore LE, Pfeiffer RM, Zhang Z, Lu KH, et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012; 118:91–100. View Full Text | PubMed | CrossRef

Murphy SK. Targeting the epigenome in ovarian cancer. Future Oncol 2012; 8:151–164. View Full Text | PubMed | CrossRef

Nayak SK, Panesar PS, Kumar H. Non-genotoxic p53-activators and their significance as antitumor therapy of future. Curr Med Chem 2011; 18:1038–1049. PubMed | CrossRef

Ng JS, Low JJH, Ilancheran A. Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2012; 26:337–345.

▪▪. No Authors Given. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615. [11]

No JH, Jeon Y-T, Kim Y-B, Song Y-S. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. GynecolObstetInvest 2011; 71:136–140.

Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol 2012; 8:55–71. View Full Text | PubMed | CrossRef

Paek J, Lee SH, Yim GW, Lee M, et al. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2011; 158:338–342. PubMed | CrossRef

Park E-K, Johnson AR, Yates DH, Thomas PS. Evaluation of ovarian cancer biomarkers in subjects with benign asbestos-related pleural diseases. Clin Chem Lab Med 2011; 49:147–150. View Full Text | PubMed | CrossRef

Park Y, Kim Y, Lee EY, Lee JH, et al. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer 2012; 130:1136–1144. PubMed | CrossRef

▪▪. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq Provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012; 14:357–366. [13]

Rai AJ, Flores RM. Association of malignant mesothelioma and asbestos related conditions with ovarian cancer: shared biomarkers and a possible etiological link? Clin Chem Lab Med 2011; 49:5–7.

Raja FA, Hook JM, Ledermann JA. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev 2012; 38:662–672. PubMed | CrossRef

Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol/Hematol 2011; 80:193–208.

▪. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3:111ra121. [23]

Sasaroli D, Gimotty PA, Pathak HB, Hammond R, et al. Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011; 12:169–180. PubMed | CrossRef

Schiavone MB, Bashir S, Herzog TJ. Biologic Therapies and Personalized Medicine in Gynecologic Malignancies. Obstet Gynecol Clin N Am 2012; 39:131.

Singh BN, Zhou HY, Li JP, Tipton T, et al. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 2011; 7:1415–1428. View Full Text | PubMed | CrossRef

Tang HY, Beer LA, Chang-Wong T, Hammond R, et al. A Xenograft Mouse Model Coupled with In-depth Plasma Proteome Analysis Facilitates Identification of Novel Serum Biomarkers for Human Ovarian Cancer. J Proteome Res 2012; 11:678–691. PubMed | CrossRef

Tempfer CB. Plasma fibrinogen as a biomarker in gynecologic cancers. Pers Med 2011; 8:501–502.

Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer. Current Pharmaceutical Design 2012; 18:2713–2719. PubMed | CrossRef

▪▪. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011; 305:1577–1584. [16]

Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol 2011; 158:119–123. PubMed | CrossRef

Zhang W, Yang HC, Wang Q, Yang ZJ, et al. Clinical Value of Combined Detection of Serum Matrix Metalloproteinase-9, Heparanase, and Cathepsin for Determining Ovarian Cancer Invasion and Metastasis. Anticancer Res 2011; 31:3423–3428. PubMed

Zhang YQ, Peng C, Wu G, Wang Y, et al. Expression of NLK and Its Potential Effect in Ovarian Cancer Chemotherapy. Int J Gynecol Cancer 2011; 21:1380–1387. View Full Text | PubMed | CrossRef

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila Pa) 2011; 4:375–383.

Ziebarth AJ, Landen CN, Alvarez RD. Molecular/Genetic Therapies in Ovarian Cancer: Future Opportunities and Challenges. Clin Obstet Gynecol 2012; 55:156–172. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Primary human papillomavirus testing in organized cervical screening

Review: (pp. 11–16)

Al-Kalbani M, McVeigh G, Nagar H, McCluggage WG. Do FIGO Stage IA and Small (≤ 2 cm) IB1 Cervical Adenocarcinomas Have a Good Prognosis and Warrant Less Radical Surgery? Int J Gynecol Cancer 2012; 22:291–295.

▪. Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012; 344:e900. doi: 10.1136/bmj.e900 [08]

▪. Arbyn M, Andersson K, Bergeron C, et al. Cervical cytology biobanks as a resource for molecular epidemiology. Methods Mol Biol 2011; 675:279–298. [03]

Biewenga P, van der Velden J, Mol BWJ, Stalpers LJA, et al. Prognostic model for survival in patients with early stage cervical cancer. Cancer 2011; 117:768–776. View Full Text | PubMed | CrossRef

Carter J, Raviv L, Sonoda Y, Chi DS, et al. Recovery issues of fertility-preserving surgery in patients with early-stage cervical cancer and a model for survivorship: the physician checklist. Int J Gynecol Cancer 2011; 21:106–116. View Full Text | PubMed | CrossRef

Chambers SK, Martinez JD. The significance of p53 isoform expression in serous ovarian cancer. Future Oncol 2012; 8:683–686. View Full Text | PubMed | CrossRef

Cibula D, Pinkavova I, Dusek L, Slama J, et al. Local control after tailored surgical treatment of early cervical cancer. Int J Gynecol Cancer 2011; 21:690–698. View Full Text | PubMed | CrossRef

Danska-Bidzinska A, Sobiczewski P, Bidzinski M, Gujski M. [Radical trachelectomy–retrospective analysis of our own case material]. Ginekol Pol 2011; 82:436–440. PubMed

▪▪. De Kok IM, van Rosmalen J, Dillner J, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012; 344:e670. doi: 10.1136/bmj.e670 [02]

▪. Dillner J, Andersson K. Biobanks collected for routine healthcare purposes: build-up and use for epidemiologic research. Methods Mol Biol 2011; 675:113–125. [04]

▪. Eklund C, Forslund O, Wallin KL, et al, WHO Human Papillomavirus Laboratory Network. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012; 50:2289–2298. doi: 10.1128/JCM.00840-12 [05]

Fagotti A, Gagliardi ML, Moruzzi C, Carone V, et al. Excisional cone as fertility-sparing treatment in early-stage cervical cancer. Fertil Steril 2011; 95:1109–1112. PubMed | CrossRef

Ferriaoli D, Buenerd A, Marchiole P, Constantini S, et al. Early Invasive Cervical Cancer During Pregnancy Different Therapeutic Options to Preserve Fertility. Int J Gynecol Cancer 2012; 22:842–849.

Gmyrek L, Jonska-Gmyrek J, Kubik P. [Fertility-conserving therapy in cervical cancer patients]. Ginekol Pol 2011; 82:696–699. PubMed

▪▪. Hakama M, Malila N, Dillner J. Randomised health services studies. Int J Cancer 2012; 131:2898–2902. doi: 10.1002/ijc.27561 [06]

Han L, Yang X-Y, Zheng A, Wang L, et al. Systematic comparison of radical vaginal trachelectomy and radical hysterectomy in the treatment of early-stage cervical cancer. Int J Gynaecol Obstet 2011; 112:149–153. PubMed | CrossRef

Helpman L, Grisaru D, Covens A. Early adenocarcinoma of the cervix: Is radical vaginal trachelectomy safe? Gynecol Oncol 2011; 123:95–98.

Hong JH, Choi JS, Lee JH, Son CE, et al. Comparison of Survival and Adverse Events between Women with Stage IB1 and Stage IB2 Cervical Cancer Treated by Laparoscopic Radical Vaginal Hysterectomy. Ann Surg Oncol 2012; 19:605–611. PubMed | CrossRef

Jadoul P, Querleu D, Squifflet J-L, Donnez J. Recurrence during pregnancy of a conservatively treated early-stage cervical squamous cell carcinoma. Fertil Steril 2011; 95:290. e213–296.

Kim CH, Abu-Rustum NR, Chi DS, Gardner GJ, et al. Reproductive outcomes of patients undergoing radical trachelectomy for early-stage cervical cancer. Gynecol Oncol 2012; 125:585–588. PubMed | CrossRef

Kim HS, Choi CH, Lim MC, Chang SJ, et al. Safe Criteria for Less Radical Trachelectomy in Patients with Early-Stage Cervical Cancer: A Multicenter Clinicopathologic Study. Ann Surg Oncol 2012; 19:1973–1979. PubMed | CrossRef

▪. Lönnberg S, Nieminen P, Luostarinen T, Anttila A. Mortality audit of the Finnish cervical cancer screening program. Int J Cancer 2012. doi: 10.1002/ijc.27844 [Epub ahead of print]. [09]

Lanowska M, Mangler M, Spek A, Grittner U, et al. Radical Vaginal Trachelectomy (RVT) Combined With Laparoscopic Lymphadenectomy Prospective Study of 225 Patients With Early-Stage Cervical Cancer. Int J Gynecol Cancer 2011; 21:1458–1464. View Full Text | PubMed | CrossRef

Lanowska M, Morawietz L, Sikora A, Raber G, et al. Prevalence of lymph nodes in the parametrium of radical vaginal trachelectomy (RVT) specimen. Gynecol Oncol 2011; 121:298–302. PubMed | CrossRef

Maneo A, Sideri M, Scambia G, Boveri S, et al. Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer. An Italian experience. Gynecol Oncol 2011; 123:557–560. PubMed | CrossRef

Marchiole P, Tigaud JD, Costantini S, Mammoliti S, et al. Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB-IIA1). Gynecol Oncol 2011; 122:484–490. PubMed | CrossRef

Martinez A, Poilblanc M, Ferron G, De Cuypere M, et al. Fertility-preserving surgical procedures, techniques. Best Pract Res Clin Obstet Gynaecol 2012; 26:407–424. PubMed | CrossRef

Mitchell S, Ogilvie G, Steinberg M, Sekikubo M, et al. Assessing women's willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in Uganda. Int J Gynaecol Obstet 2011; 114:111–115. PubMed | CrossRef

Murphy SK. Targeting the epigenome in ovarian cancer. Future Oncol 2012; 8:151–164. View Full Text | PubMed | CrossRef

Nam JH, Park JY, Kim DY, Kim JH, et al. Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. Ann Oncol 2012; 23:903–904. View Full Text | PubMed | CrossRef

Nick AM, Frumovitz MM, Soliman PT, Schmeler KM, et al. Fertility sparing surgery for treatment of early-stage cervical cancer: open vs. robotic radical trachelectomy. Gynecol Oncol 2012; 124:276–280. PubMed | CrossRef

Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol 2012; 8:55–71. View Full Text | PubMed | CrossRef

Orfanoudaki IM, Kappou D, Sifakis S. Recent advances in optical imaging for cervical cancer detection. Arch Gynecol Obstet 2011; 284:1197–1208. PubMed | CrossRef

Ottosen C. Trachelectomy for cancer of the cervix: dargent's operation. Vaginal hysterectomy for early cancer of the cervix stage IA1 and CIN III. Best Pract Res Clin Obstet Gynaecol 2011; 25:217–225. PubMed | CrossRef

Park JY, Kim DY, Kim JH, Kim YM, et al. Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer. Ann Oncol 2011; 22:59–67. PubMed | CrossRef

Raju SK, Papadopoulos AJ, Montalto SA, Coutts M, et al. Fertility-Sparing Surgery for Early Cervical Cancer-Approach to Less Radical Surgery. Int J Gynecol Cancer 2012; 22:311–317. View Full Text | PubMed | CrossRef

Rodriguez Villalba S, Diaz-Caneja Planell C, Cervera Grau JM. Current opinion in cervix carcinoma. Clin Transl Oncol 2011; 13:378–384. PubMed

▪▪. Ronco G, Biggeri A, Confortini M, et al. Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev 36(3–4 Suppl. 1)2012:e1–e72. [01]

▪. Söderlund-Strand A, Eklund C, Kemetli L, et al. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol 2011; 205:145e1–145e6. [07]

Saso S, Ghaem-Maghami S, Chatterjee J, Naji O, et al. Abdominal radical trachelectomy in West London. Bjog 2012; 119:187–193. PubMed | CrossRef

Shepherd JH. Cervical cancer. Best Pract Res Clin Obstet Gynaecol 2012; 26:293–309. PubMed | CrossRef

▪. Silfverdal L, Kemetli L, Sparén P, et al. Risk of invasive cervical cancer in relation to clinical investigation and treatment after abnormal cytology: a population-based case–control study. Int J Cancer 2011; 129:1450–1458. doi: 10.1002/ijc.25749 [10]

Singh BN, Zhou HY, Li JP, Tipton T, et al. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 2011; 7:1415–1428. View Full Text | PubMed | CrossRef

Singh P, Tripcony L, Nicklin J. Analysis of Prognostic Variables, Development of Predictive Models, and Stratification of Risk Groups in Surgically Treated FIGO Early-Stage (IA-IIA) Carcinoma Cervix. Int J Gynecol Cancer 2012; 22:115–122. PubMed | CrossRef

Small W, Strauss JB, Jhingran A, Yashar CM, et al. ACR Appropriateness Criteria (R) Definitive Therapy for Early-Stage Cervical Cancer. Am J Clin Oncol-Cancer Clin Trials 2012; 35:399–405. View Full Text | PubMed | CrossRef

Tinelli R, Malzoni M, Cosentino F, Perone C, et al. Robotics versus laparoscopic radical hysterectomy with lymphadenectomy in patients with early cervical cancer: a multicenter study. Ann Surg Oncol 2011; 18:2622–2628. PubMed | CrossRef

Wolfson AH, Varia MA, Moore D, Rao GG, et al. ACR Appropriateness Criteria (R) role of adjuvant therapy in the management of early stage cervical cancer. Gynecol Oncol 2012; 125:256–262. PubMed | CrossRef

Xu L, Sun FQ, Wang ZH. Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review. Acta Obstet Gynecol Scand 2011; 90:1200–1209. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
FDG PET/CT in monitoring response to treatment in gynecological malignancies

Review: (pp. 17–22)

▪. Amit A, Schink J, Reiss A, Lowenstein L. PET/CT in gynecologic cancer: present applications and future prospects–a clinician's perspective. Obstet Gynecol Clin North Am 2011; 38:1–21. vii. [02]

Dorn J, Magdolen V, Gkazepis A, Gerte T, et al. Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients' survival. Ann Oncol 2011; 22:1783–1790. View Full Text | PubMed | CrossRef

Kamimori T, Sakamoto K, Fujiwara K, Umayahara K, et al. Parametrial involvement in FIGO stage IB1 cervical carcinoma diagnostic impact of tumor diameter in preoperative magnetic resonance imaging. Int J Gynecol Cancer 2011; 21:349–354. View Full Text | PubMed

Liu FY, Chao A, Lai CH, Chou HH, et al. Metabolic tumor volume by (18) F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol 2012; 125: 566–571. PubMed | CrossRef

Palma MD, Gregianin M, Fiduccia P, Evangelista L, et al. PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis. Crit Rev Oncol/Hematol 2012; 83:84–98.

Sandvik RM, Jensen PT, Hendel HW, Palle C. Positron emission tomography-computed tomography has a clinical impact for patients with cervical cancer. Dan Med Bull 2011; 58:A4240. PubMed

▪▪. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Metabolic response on posttherapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2012; 83:185–190. [38]

Schwarz JK, Wahab S, Grigsby PW. Prospective phase i-ii trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients. Int J Radiat Oncol Biol Phys 2011; 81:1258–1263. PubMed | CrossRef

Whitlock EP, Vesco KK, Eder M, Lin JS, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 687–697W214-685. View Full Text | PubMed | CrossRef

Back to Top | Article Outline
Perioperative care in gynecologic oncology

Review: (pp. 23–28)

Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol 2012; 124:477–489.

Acheson N, Crawford R. Letter to the Editor on ‘‘Preoperative Bowel Preparation in Gynecologic Oncology: A Review of Practice and an Impetus to Change’' by Wells et al. Int J Gyn Cancer 2011;21(6):1135-1142. Int J Gynecol Cancer 2012; 22:530. View Full Text | PubMed | CrossRef

Backes FJ, Brudie LA, Farrell MR, Ahmad S, et al. Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol 2012; 125:546–551. PubMed | CrossRef

▪▪. Barnett S, Moonesinghe SR. Clinical risk scores to guide perioperative management. Postgrad Med J 2011; 87:535–541. [06]

Brotto LA, Erskine Y, Carey M, Ehlen T, et al. A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. Gynecol Oncol 2012; 125:320–325.

▪. Brummer TH, Jalkanen J, Fraser J, et al. FINHYST, a prospective study of 5279 hysterectomies: complications and their risk factors. Hum Reprod 2011; 26:1741–1751. [28]

▪. Clarke-Pearson DL, Abaid LN. Prevention of venous thromboembolic events after gynecologic surgery. Obstet Gynecol 2012; 119:155–167. [34]

▪. Cohen SL, Einarsson JI. The role of mechanical bowel preparation in gynecologic laparoscopy. Rev Obstet Gynecol 2011; 4:28–31. [15]

▪. Erekson EA, Yip SO, Ciarleglio MM, Fried TR. Postoperative complications after gynecologic surgery. Obstet Gynecol 2011; 118:785–793. [02]

▪▪. Fanning J, Valea FA. Perioperative bowel management for gynecologic surgery. Am J Obstet Gynecol 2011; 205: 309–314. [13]

Graybill WS, Frumovitz M, Nick AM, Wei CM, et al. Impact of smoking on perioperative pulmonary and upper respiratory complications after laparoscopic gynecologic surgery. Gynecol Oncol 2012; 125:556–560. PubMed | CrossRef

▪. Hitos K, Wain GV, Fletcher JP. Venous thromboembolism following gynecological surgery for suspected or confirmed malignancy. Aust N Z J Obstet Gynaecol 2012; 52:23–27. [36]

Hoeks SE, Bouw E, Poldermans D. Quality assurance in perioperative care. Baillieres Best Pract Res Clin Gastroenterol 2011; 25:435–441. PubMed | CrossRef

Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, et al. Hormone replacement therapy in gynecologic cancer survivors: Why not? Gynecol Oncol 2011; 122:447–454.

Kahokehr A, Robertson P, Sammour T, Soop M, et al. Perioperative care: a survey of New Zealand and Australian colorectal surgeons. Colorectal Dis 2011; 13:1308–1313. View Full Text | PubMed | CrossRef

Martino MA, George JG, Chen CC, Galic V, et al. Preoperative Enoxaparin Is Safe to Use in Major Gynecologic Surgery for Prophylaxis of Venous Thromboembolism A Retrospective Cohort Study. Int J Gynecol Cancer 2012; 22:681–685. View Full Text | PubMed | CrossRef

▪▪. No Authors Given. Phoolcharoen N, Nilgate S, Rattanapuntamanee O, et al. A randomized controlled trial comparing ceftriaxone with cefazolin for antibiotic prophylaxis in abdominal hysterectomy. Int J Gynaecol Obstet 2012; 119:11–13. [29]

Papadakos J, Bussiere-Cote S, Abdelmutti N, Catton P, et al. Informational needs of gynecologic cancer survivors. Gynecol Oncol 2012; 124:452–457. PubMed | CrossRef

Quick AM, Seamon LG, Abdel-Rasoul M, Salani R, et al. Sexual Function After Intracavitary Vaginal Brachytherapy for Early-Stage Endometrial Carcinoma. Int J Gynecol Cancer 2012; 22:703–708. View Full Text | PubMed | CrossRef

▪▪. Rahn DD, Mamik MM, Sanses TVD, et al. Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol 2011; 118:1111–1125. [33]

Rahn DD, Mamik MM, Sanses TVD, Matteson KA, et al. Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol 2011; 118:1111–1125. View Full Text | PubMed | CrossRef

Rezk Y, Timmins PF, Smith HS. Palliative Care in Gynecologic Oncology. The American Journal of Hospice & Palliative Care Online 2011; 28:356–374.

Salani R, Backes FJ, Fung MFK, Holschneider CH, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466–478. View Full Text | PubMed | CrossRef

▪. Salkind AR, Rao KC. Antibiotic prophylaxis to prevent surgical site infections. Am Fam Physician 2011; 83:585–590. [30]

▪. Shiozaki T, Tabata T, Motohashi T, et al. Preoperative management of patients with gynecologic malignancy complicated by existing venous thromboembolism. Eur J Obstet Gynecol Reprod Biol 2012; 164:85–88. [38]

Silvester W, Detering K. Advance directives, perioperative care and end-of-life planning. Best Pract Res Clin Anaesthesiol 2011; 25:451–460.

Singh S, Laughingwell R, Rosenblum NG. Perioperative morbidity associated with medically necessary panniculectomy in gynecologic oncology surgery. Int J Gynecol Obstet 2012; 118:47–51. PubMed | CrossRef

▪▪. Van Eyk N, van Schalkwyk J, Infectious Diseases Committee. Antibiotic prophylaxis in gynaecologic procedures. J Obstet Gynaecol Can 2012; 34:382–391. [31]

Var T, Gungor T, Tonguc E, Ozdener T, et al. The conservative treatment of postoperative chylous ascites in gynecologic cancers: four case reports. Arch Gynecol Obstet 2012; 285:849–851. PubMed | CrossRef

▪. Wells T, Plante M, McAlpine JN, Communities of Practice Groups on behalf of the Society of Gynecologic Oncologists of Canada. Preoperative bowel preparation in gynecologic oncology: a review of practice patterns and an impetus to change. Int J Gynecol Cancer 2011; 21:135–142. [14]

▪. Whitworth JM, Schneider KE, Frederick PJ, et al. Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy. Int J Gynecol Cancer 2011; 21:1131–1133. [32]

Yang EJ, Lim JY, Rah UW, Kim YB. Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: A randomized controlled trial. Gynecol Oncol 2012; 125:705–711. PubMed | CrossRef

▪. Yang LC, Arden D, Lee TT, et al. Mechanical bowel preparation for gynecologic laparoscopy: a prospective randomized trial of oral sodium phosphate solution versus single sodium phosphate enema. J Minim Invasive Gynecol 2011; 18:149–156. [17]

Back to Top | Article Outline
Updates in therapy for uterine serous carcinoma

Review: (pp. 29–37)

Acholonu UC, Chang-Jackson SCR, Radjabi AR, Nezhat FR. Laparoscopy for the Management of Early-Stage Endometrial Cancer: From Experimental to Standard of Care. J Mimim Invasive Gynecol 2012; 19:434–442.

Backes FJ, Brudie LA, Farrell MR, Ahmad S, et al. Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol 2012; 125:546–551. PubMed | CrossRef

Bahng AY, Dagan A, Bruner DW, Lin LLL. Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer. Int J Radiat Oncol Biol Phys 2012; 82:667–673. PubMed | CrossRef

Bakkum-Gamez JN, Mariani A, Dowdy SC, Weaver AL, et al. The impact of surgical guidelines and periodic quality assessment on the staging of endometrial cancer. Gynecol Oncol 2011; 123:58–64. PubMed | CrossRef

Banno K, Kisu I, Yanokura M, Tsuji K, et al. Progestin therapy for endometrial cancer: The potential of fourth-generation progestin. Int J Oncol 2012; 40:1755–1762. PubMed

Barlin JN, Dao F, Zgheib NB, Ferguson SE, et al. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2012; 125:621–624. PubMed | CrossRef

▪. Bellone S, Roque D, Cocco E, et al. Down-regulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitizes uterine serous carcinoma overexpressing HER2/neu to complement and antibody-dependent-cell-cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. Br J Cancer 2012; 106:1543–1550. [98]

Ben Arie A, Lavie O, Gdalevich M, Voldarsky M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Ejso 2012; 38:166–169.

Bendifallah S, Koskas M, Ballester M, Genin AS, et al. The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis - art. no. e1-11. Am J Obstet Gynecol 2012; 206:11. PubMed

Bernardini MQ, Gien LT, Tipping H, Murphy J, et al. Surgical Outcome of Robotic Surgery in Morbidly Obese Patient With Endometrial Cancer Compared to Laparotomy. Int J Gynecol Cancer 2012; 22:76–81. PubMed | CrossRef

Bertelsen K, Ortoft G, Hansen ES. Survival of Danish Patients With Endometrial Cancer in the Intermediate-Risk Group Not Given Postoperative Radiotherapy The Danish Endometrial Cancer Study (DEMCA). Int J Gynecol Cancer 2011; 21:1191–1199. View Full Text | PubMed

Bignotti E, Ravaggi A, Romani C, Falchetti M, et al. Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma Implications for Immunotherapy With hRS7, a Humanized Anti-Trop-2 Monoclonal Antibody. Int J Gynecol Cancer 2011; 21:1613–1621. View Full Text | PubMed | CrossRef

Boruta DM, Growdon WB, McCann CK, Garrett LA, et al. Evolution of surgical management of early-stage endometrial cancer - art. no. 565.e1. Am J Obstet Gynecol 2011; 205:E1. PubMed

Carrara L, Gadducci A, Landoni F, Maggino T, et al. Could Different Follow-Up Modalities Play a Role in the Diagnosis of Asymptomatic Endometrial Cancer Relapses? An Italian Multicentric Retrospective Analysis. Int J Gynecol Cancer 2012; 22:1013–1019. View Full Text | PubMed | CrossRef

Chen XL, Xiang YB, Long JR, Cai H, et al. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 2012; 118:3356–3364. PubMed | CrossRef

Chino JP, Jones E, Berchuck A, Secord AA, et al. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys 2012; 82:1872–1879. PubMed | CrossRef

▪. Colas E, Pedrola N, Devis L, et al. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 2012; 14:715–720. [72]

Cooke EW, Pappas L, Gaffney DK. Does the Revised International Federation of Gynecology and Obstetrics Staging System for Endometrial Cancer Lead to Increased Discrimination in Patient Outcomes? Cancer 2011; 117:4231–4237.

Creutzberg CL, Nout RA. The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends. Curr Oncol Rep 2011; 13:472–478. PubMed | CrossRef

Crosbie EJ, Roberts C, Qian WD, Swart AM, et al. Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial. Eur J Cancer 2012; 48:853–864.

Darai E, Zacharopoulou C, Touboul C, Chereau E, et al. Sentinel node procedure and endometrial cancer: senti-endo results. Bull Cancer 2012; 99:35–41. PubMed

▪. Dewdney SB, Kizer NT, Andaya AA, et al. Uterine serous carcinoma: increased familial risk for Lynch-associated malignancies. Cancer Prev Res 2012; 5:435–443. [94]

Di Donato V, Perniola G, Marchetti C, Loprete E, et al. Minimally Invasive Surgical Approach for Treatment of Isolated Endometrial Cancer Recurrence in an Ultra-Morbidly Obese Patient. J Mimim Invasive Gynecol 2011; 18:820–822.

Di Legge A, Trivellizzi IN, Moruzzi MC, Pesce A, et al. Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer. Int J Gynecol Cancer 2011; 21:1446–1451. View Full Text | PubMed | CrossRef

Dogan NU, Gungor T, Karsli F, Ozgu E, et al. To What Extent Should Para-aortic Lymphadenectomy Be Carried Out for Surgically Staged Endometrial Cancer? Int J Gynecol Cancer 2012; 22:607–610.

Eddib A, Allaf B, Lee J, Yeh J. Risk for Advanced-Stage Endometrial Cancer in Surgical Specimens from Patients with Complex Endometrial Hyperplasia with Atypia. GynecolObstetInvest 2012; 73:38–42.

Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, et al. Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy. Cancer Chemother Pharmacol 2011; 68:1603–1610. PubMed | CrossRef

Eichbaum MHR, Sohn C. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer 2011; 117:3529author reply 3529–3530.

▪. Einstein MH, Frimer M, Kuo DY, et al. Phase II trial of adjuvant pelvic radiation ‘sandwiched’ between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol 2012; 124:21–25. [39]

El-Safadi S, Sauerbier A, Hackethal A, Munstedt K. Body weight changes after the diagnosis of endometrial cancer and their influences on disease-related prognosis. Arch Gynecol Obstet 2012; 285:1725–1729. PubMed | CrossRef

El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther 2012; 12:41–49. View Full Text | PubMed | CrossRef

El Sahwi KS, Hooper C, De Leon MC, Gallo TN, et al. Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol 2012; 124:260–264.

Fabrini MG, Gadducci A, Perrone F, La Liscia C, et al. Relationship between Interval from Surgery to Radiotherapy and Local Recurrence Rate in Patients with Endometrioid-type Endometrial Cancer: a Retrospective Mono-institutional Italian Study. Anticancer Res 2012; 32:169–173. PubMed

Fagotti A, Boruta DM, Scambia G, Fanfani F, et al. First 100 early endometrial cancer cases treated with laparoendoscopic single-site surgery: a multicentric retrospective study - art. no. 353.e1. Am J Obstet Gynecol 2012; 206:E1. PubMed

Fujiwara K, Egawa-Takata T, Ueda Y, Kimura T, et al. Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma. Arch Gynecol Obstet 2012; 285:1447–1453. PubMed | CrossRef

Fumagalli I, Leblanc E, Nickers P. Radiation therapy versus chemoradiation as adjuvant treatment in high-risk endometrial cancer. Bull Cancer 2012; 99:79–83. PubMed

Gadducci A, Cosio S, Fabrini MG, Guerrieri ME, et al. Analysis of Failures in Patients with FIGO Stage IIIc(1)-IIIc(2) Endometrial Cancer. Anticancer Res 2012; 32:201–205. PubMed

Gaztanaga M, Cambeiro M, Villafranca E, Vila M, et al. Long-term results of 1-week intravaginal high-dose-rate brachytherapy alone for endometrial cancer. Brachytherapy 2012; 11:119–124. PubMed | CrossRef

Gonzalez-Rodilla I, Verna V, Munoz AB, Estevez J, et al. Expression of the Apoptosis-related Genes Bcl-2 and p53 in Clinical Samples from Endometrial Carcinoma Patients. Anticancer Res 2011; 31:4191–4193. PubMed

Grisham RN, Adaniel C, Hyman DM, Ma WN, et al. Gemcitabine for Advanced Endometrial Cancer A Retrospective Study of the Memorial Sloan-Kettering Cancer Center Experience. Int J Gynecol Cancer 2012; 22:807–811. View Full Text | PubMed | CrossRef

Hasegawa K, Torii Y, Ishii R, Oe S, et al. Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet 2011; 284:1515–1521. PubMed | CrossRef

He SM, Xing FQ, Sui H, Wu YM, et al. Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. Med Sci Monit 2011; 17:CR618–CR625. PubMed

Hill EK, Dizon DS. Medical Therapy of Endometrial Cancer Current Status and Promising Novel Treatments. Drugs 2012; 72:705–713. View Full Text | PubMed | CrossRef

Hogberg T. What is the Role of Chemotherapy in Endometrial Cancer? Curr Oncol Rep 2011; 13:433–441.

Hwang JH, Lim MC, Seo SS, Kang S, et al. Outcomes and toxicities for the treatment of stage IVB cervical cancer. Arch Gynecol Obstet 2012; 285:1685–1693. PubMed | CrossRef

Kalogera E, Scholler N, Powless C, Weaver A, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 2012; 124:270–275. PubMed | CrossRef

Kang S, Kang WD, Chung HH, Jeong DH, et al. Preoperative Identification of a Low-Risk Group for Lymph Node Metastasis in Endometrial Cancer: A Korean Gynecologic Oncology Group Study. J Clin Oncol 2012; 30:1329–1334. PubMed | CrossRef

Kasuya G, Ogawa K, Iraha S, Nagai Y, et al. Severe Late Complications in Patients with Uterine Cancer Treated with Postoperative Radiotherapy. Anticancer Res 2011; 31:3527–3533. PubMed

▪. Kiess AP, Damast S, Makker V, et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol 2012; 127:321–325. [35]

Kim HS, Kim HY, Park CY, Lee JM, et al. Lymphadenectomy increases the prognostic value of the revised 2009 FIGO staging system for endometrial cancer: A multi-center study. Ejso 2012; 38:230–237.

Kim HS, Suh DH, Kim MK, Chung HH, et al. Systematic Lymphadenectomy for Survival in Patients with Endometrial Cancer: A Meta-analysis. Jpn J Clin Oncol 2012; 42:405–412. View Full Text | PubMed | CrossRef

Koskas M, Chabbert-Buffet N, Bendifallah S, Luton D, et al. Prognostic Value of the 2009 FIGO Staging for Endometrial Cancer An Illustration of the E3N Cohort. Int J Gynecol Cancer 2012; 22:447–451. View Full Text | PubMed | CrossRef

▪▪. Kuhn E, Wu R-C, Wu G, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Ca Instit 2012; 104:1503–1513. [51]

Leenen CHM, van Lier MGF, van Doorn HC, van Leerdam ME, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. Gynecol Oncol 2012; 125:414–420. PubMed | CrossRef

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, et al. Endometrial Cancer. Obstet Gynecol Clin N Am 2012; 39:255.

Lheureux S, Joly F. Endometrial cancer: place for adjuvant chemotherapy. Bull Cancer 2012; 99:85–91. PubMed

Lomnytska MI, Becker S, Gemoll T, Lundgren C, et al. Impact of genomic stability on protein expression in endometrioid endometrial cancer. Br J Cancer 2012; 106:1297–1305.

Lowery WJ, Gehrig PA, Ko E, Secord AA, et al. Surgical staging for endometrial cancer in the elderly - Is there a role for lymphadenectomy? Gynecol Oncol 2012; 126:12–15.

Lowery WJ, Leath CA, Robinson RD. Robotic surgery applications in the management of gynecologic malignancies. J Surg Oncol 2012; 105:481–487. View Full Text | PubMed | CrossRef

Mais V, Cirronis MG, Piras B, Silvetti E, et al. Intraoperative lymphatic mapping techniques for endometrial cancer. Expert Rev Anticancer Ther 2011; 11:83–93. View Full Text | PubMed | CrossRef

Maneschi F, Ceccacci I, Perugini A, Pane C, et al. Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings. Arch Gynecol Obstet 2012; 285:521–527. PubMed | CrossRef

Martino MA, Shubella J, Thomas MB, Morcrette RM, et al. A cost analysis of postoperative management in endometrial cancer patients treated by robotics versus laparoscopic approach. Gynecol Oncol 2011; 123:528–531. PubMed | CrossRef

Mazeron R, Khodari W, Gilmore J, Champoudry J, et al. Postoperative vaginal brachytherapy in endometrial cancer. Bull Cancer 2012; 99:69–77. PubMed

Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, et al. Pair-Box (PAX8) protein-positive expression is associated with poor disease outcome in women with endometrial cancer. Br J Cancer 2012; 107:370–374. PubMed | CrossRef

Milam MR, Java J, Walker JL, Metzinger DS, et al. Nodal Metastasis Risk in Endometrioid Endometrial Cancer. Obstet Gynecol 2012; 119:286–292. View Full Text | PubMed | CrossRef

Mok ZW, Yong EL, Low JJH, Ng JSY. Clinical Outcomes in Endometrial Cancer Care When the Standard of Care Shifts From Open Surgery to Robotics. Int J Gynecol Cancer 2012; 22:819–825. View Full Text | PubMed | CrossRef

Morotti M, Menada MV, Moioli M, Sala P, et al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecol Oncol 2012; 125:536–540. PubMed | CrossRef

Mountzios G, Pectasides D, Bournakis E, Pectasides E, et al. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol/Hematol 2011; 79:278–292.

Mu N, Zhu YX, Wang YM, Zhang HY, et al. Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol 2012; 125:751–757. PubMed | CrossRef

Musa F, Huang M, Adams B, Pirog E, et al. Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecol Oncol 2012; 125:541–545. PubMed | CrossRef

Musonda P, Burbos N, Duncan TJ, Crocker SG, et al. Comparing the performance of two clinical models in estimating the risk of endometrial cancer in symptomatic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2011; 159:433–438. PubMed | CrossRef

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 2012; 126:186–191.

Narayan K, Khaw P, Bernshaw D, Mileshkin L, et al. Prognostic Significance of Lymphovascular Space Invasion and Nodal Involvement in Intermediate- and High-Risk Endometrial Cancer Patients Treated With Curative Intent Using Surgery and Adjuvant Radiotherapy. Int J Gynecol Cancer 2012; 22:260–266. View Full Text | PubMed | CrossRef

Naumann RW. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. Gynecol Oncol 2011; 123:411–420.

Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012; 48:1638–1648. PubMed | CrossRef

Paek J, Nam EJ, Lee M, Yim GW, et al. Two-Port Access Versus Conventional Staging Laparoscopy for Endometrial Cancer. Int J Gynecol Cancer 2012; 22:515–520. View Full Text | PubMed | CrossRef

Page BR, Pappas L, Cooke EW, Gaffney DK. Does the FIGO 2009 Endometrial Cancer Staging System More Accurately Correlate With Clinical Outcome in Different Histologies? Revised Staging, Endometrial Cancer, Histology. Int J Gynecol Cancer 2012; 22:593–598. View Full Text | PubMed | CrossRef

Palomba S, Falbo A, Russo T, La Sala GB. Port-Site Metastasis After Laparoscopic Surgical Staging of Endometrial Cancer: A Systematic Review of the Published and Unpublished Data. J Mimim Invasive Gynecol 2012; 19:531–537.

▪. Pennington KT, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2012. doi://10.1002/cncr.27720. [Epub ahead of print] [85]

Phipps AI, Doherty JA, Voigt LF, Hill DA, et al. Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control 2011; 22:1639–1646. PubMed | CrossRef

Poilblanc M, Samouelian V, Querleu D. Ovarian preservation during treatment of early stage endometrial cancer. Bull Cancer 2012; 99:61–68. PubMed

Rabischong B, Larrain D, Canis M, Le Bouedec G, et al. Long-Term Follow-Up After Laparoscopic Management of Endometrial Cancer in the Obese: A Fifteen-Year Cohort Study. J Mimim Invasive Gynecol 2011; 18:589–596.

Raja FA, Hook JM, Ledermann JA. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev 2012; 38:662–672. PubMed | CrossRef

Ray-Coquard I, Chauvin F, Leblanc E, Caux C, et al. PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved. Bull Cancer 2012; 99:479–498. PubMed

Rivard C, Salhadar A, Kenton K. New Challenges in Detecting, Grading, and Staging Endometrial Cancer After Uterine Morcellation. J Mimim Invasive Gynecol 2012; 19:313–316.

Rowlands IJ, Nagle CM, Spurdle AB, Webb PM. Gynecological conditions and the risk of endometrial cancer. Gynecol Oncol 2011; 123:537–541. PubMed | CrossRef

Ryan P, Mulligan AM, Aronson M, Ferguson SE, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 2012; 118:681–688. PubMed | CrossRef

Saarelainen SK, Koobi L, Jarvenpaa R, Laurila M, et al. The preoperative assessment of deep myometrial invasion by three-dimensional ultrasound versus MRI in endometrial carcinoma. Acta Obstet Gynecol Scand 2012; 91:983–990.

Santoso JT, Barton G, Riedley-Malone S, Wan JY. Obesity and perioperative outcomes in endometrial cancer surgery. Arch Gynecol Obstet 2012; 285:1139–1144. PubMed | CrossRef

Sany O, Singh K, Jha S. Correlation between preoperative endometrial sampling and final endometrial cancer histology. Eur J Gynaecol Oncol 2012; 33:142–144. PubMed

Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011; 205:518–525. View Full Text | PubMed | CrossRef

Sharma C, Deutsch I, Lewin SN, Burke WM, et al. Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer - art. no. 562.e1. Am J Obstet Gynecol 2011; 205:E1. PubMed

Shin KE, Park BK, Kim CK, Bae DS, et al. MR staging accuracy for endometrial cancer based on the new FIGO stage. Acta Radiol 2011; 52:818–824. PubMed | CrossRef

Sorbe B, Horvath G, Andersson H, Boman K, et al. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma-a prospective randomized study. Int J Radiat Oncol Biol Phys 2012; 82:1249–1255. PubMed | CrossRef

Spencer R, Schorge J, Del Carmen M, Goodman A, et al. Laparoscopic Surgery for Endometrial Cancer: Why Don't All Patients Go Home the Day After Surgery? J Mimim Invasive Gynecol 2012; 19:95–100.

Tang KY, Gardiner SK, Gould C, Osmundsen B, et al. Robotic surgical staging for obese patients with endometrial cancer - art. no. 513.e1. Am J Obstet Gynecol 2012; 206:E1. PubMed

Tazi Y, Pautier P, Lhomme C. Systemic therapy for advanced endometrial cancer. Bull Cancer 2012; 99:93–97. PubMed

▪. Todeschini P, Cocco E, Bellone S, et al. HER2/Neu extracellular domain shedding in uterine serous carcinomas: implications for immunotherapy with trastuzumab. Br J Cancer 2011; 105:1176–1182. [109]

Togami S, Sasajima Y, Oi T, Ishikawa M, et al. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 2012; 103:926–932.

Tsoref D, Oza AM. Recent advances in systemic therapy for advanced endometrial cancer. Curr Opin Oncol 2011; 23:494–500. View Full Text | PubMed | CrossRef

Vance S, Yechieli R, Cogan C, Hanna R, et al. The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. Gynecol Oncol 2012; 126:16–19. PubMed | CrossRef

▪. Varughese J, Cocco E, Bellone S, et al. Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer 2011; 117:3163–3172. [96]

Venkat P, Chen LM, Young-Lin N, Kiet TK, et al. An economic analysis of robotic versus laparoscopic surgery for endometrial cancer: Costs, charges and reimbursements to hospitals and professionals. Gynecol Oncol 2012; 125:237–240. PubMed | CrossRef

Villavicencio A, Aguilar G, Acuna J, Gabler F, et al. The identification of two subgroups of obese women with differing endometrial proliferation levels: potential consequences in the development of endometrial cancer. Int J Obes 2012; 36:1012–1015. View Full Text | PubMed | CrossRef

▪. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer: a clinical and pathological evaluation. Gynecol Oncol 2012; 124:15–20. [07]

Voss MA, Ganesan R, Ludeman L, McCarthy K, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol 2012; 124:15–20. PubMed | CrossRef

▪▪. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012; 30:695–700. [19]

Wang YM, Cui M, Zheng LQ. Genetic polymorphisms in the estrogen receptor-a gene and the risk of endometrial cancer: a meta-analysis. Acta Obstet Gynecol Scand 2012; 91:911–916. View Full Text | PubMed

Yang TYO, Cairns BJ, Allen N, Sweetland S, et al. Postmenopausal endometrial cancer risk and body size in early life and middle age: prospective cohort study. Br J Cancer 2012; 107:169–175.

Zeleniuch-Jacquotte A, Shore RE, Afanasyeva Y, Lukanova A, et al. Postmenopausal circulating levels of 2-and 16 alpha-hydroxyestrone and risk of endometrial cancer. Br J Cancer 2011; 105:1458–1464. PubMed | CrossRef

Zhang H, Cui J, Jia L, Hong SH, et al. Comparison of laparoscopy and laparotomy for endometrial cancer. Int J Gynecol Obstet 2012; 116:185–191. PubMed | CrossRef

Back to Top | Article Outline
Breast cancer
Updates in the treatment of basal/triple-negative breast cancer

Review: (pp. 40–48)

Adamo V, Ricciardi GRR, De Placido S, Colucci G, et al. Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience. Eur J Cancer 2012; 48:642–647. PubMed | CrossRef

Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, et al. Impact of Body Mass Index on Clinical Outcomes in Triple-Negative Breast Cancer. Cancer 2011; 117: 4132–4140. PubMed | CrossRef

Bayraktar S, Hernadez-Aya LF, Lei XD, Meric-Bernstam F, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118:1202–1211. PubMed | CrossRef

Befort CA, Klemp JR, Austin HL, Perri MG, et al. Outcomes of a weight loss intervention among rural breast cancer survivors. Breast Cancer Res Treat 2012; 132:631–639. View Full Text | PubMed | CrossRef

Berkey CS, Tamimi RM, Rosner B, Frazier AL, et al. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer 2012; 118: 2796–2803. View Full Text | PubMed | CrossRef

Bilici A, Arslan C, Altundag K. Promising therapeutic options in triple-negative breast cancer. J 2012; 17:209–222.

▪. Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase ii study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615–2623. [62]

Cho EY, Chang MH, Choi YL, Lee JE, et al. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol 2011; 68:753–761. PubMed | CrossRef

de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137:183–192.

Eckstein N, Haas B. Platinum-based chemotherapy in triple negative breast cancer. Dtsch Med Wochenschr 2012; 137:333–336. PubMed

Eiermann W, Bergh J, Cardoso F, Conte P, et al. Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012; 21:20–26. PubMed | CrossRef

Fornier M, Fumoleau P. The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment. Breast J 2012; 18:41–51. View Full Text | PubMed | CrossRef

Fumagalli C, Pruneri G, Possanzini P, Manzotti M, et al. Methylation of O-6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 2012; 134:131–137. View Full Text | PubMed | CrossRef

Gutwein LG, Al-Quran SZ, Fernando S, Fletcher BS, et al. Tumor Endothelial Marker 8 Expression in Triple-negative Breast Cancer. Anticancer Res 2011; 31:3417–3422. PubMed

Houvenaeghel G, Bannier M, Nos C, Giard S, et al. Non sentinel node involvement prediction for sentinel node micrometastases in breast cancer: Nomogram validation and comparison with other models. Breast 2012; 21:204–209. PubMed

Iwase S, Yamamoto D, Kuroda Y, Kawaguchi T, et al. Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticancer Res 2011; 31:1483–1487. PubMed

Kau P, Nagaraja GM, Zheng HY, Gizachew D, et al. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease - art. no. 120. BMC Cancer 2012; 12:27.

Kong FL, Kim EE, Yang DJ. Targeted Nuclear Imaging of Breast Cancer: Status of Radiotracer Development and Clinical Applications. Cancer Biother Radiopharm 2012; 27:105–112. PubMed | CrossRef

Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, et al. Predictors of Pathologic Complete Response After Standard Neoadjuvant Chemotherapy in Triple-negative Breast Carcinoma. Appl Immunohistochem 2012; 20:334–339. View Full Text | PubMed | CrossRef

Lara-Medina F, Perez-Sanchez V, Saavedra-Perez D, Blake-Cerda M, et al. Triple-Negative Breast Cancer in Hispanic Patients High Prevalence, Poor Prognosis, and Association With Menopausal Status, Body Mass Index, and Parity. Cancer 2011; 117:3658–3669. PubMed | CrossRef

Lee LJ, Alexander B, Schnitt SJ, Comander A, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011; 117:3093–3100. View Full Text | PubMed | CrossRef

▪▪. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750–2767. [10]

Lin C, Chien SY, Kuo SJ, Chen LS, et al. A 10-year Follow-up of Triple-negative Breast Cancer Patients in Taiwan. Jpn J Clin Oncol 2012; 42:161–167. View Full Text | PubMed | CrossRef

Lips EH, Mulder L, de Ronde JJ, Mandjes IAM, et al. Neoadjuvant chemotherapy in ER+HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012; 131:827–836. View Full Text | PubMed | CrossRef

▪▪. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18:510–523. [39]

Masuda N, Yasojima H, Mizutani M, Yamamura J. [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan]. Gan To Kagaku Ryoho 2012; 39:512–518. PubMed

Munzone E, Botteri E, Sciandivasci A, Curigliano G, et al. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res Treat 2012; 134:277–282. View Full Text | PubMed | CrossRef

▪▪. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29(Suppl):abstr 1007. [36]

Ono M, Tsuda H, Shimizu C, Yamamoto S, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012; 132:793–805. View Full Text | PubMed | CrossRef

Ozcinar B, Guler SA, Kocaman N, Ozkan M, et al. Breast cancer related lymphedema in patients with different loco-regional treatments. Breast 2012; 21:361–365. PubMed | CrossRef

Park S, Koo JS, Kim MS, Park HS, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012; 21:50–57. PubMed | CrossRef

▪▪. Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18:1655–1662. [38]

▪▪. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 16(Suppl 1)2011:61–70. [12]

▪. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5:5–23. [11]

Rakha EA, Chan S. Metastatic Triple-negative Breast Cancer. Clin Oncol (R Coll Radiol) 2011; 23:587–600.

Schubert A, Hawighorst T, Emons G, Grundker C. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. Breast Cancer Res Treat 2011; 130:783–790. View Full Text | PubMed | CrossRef

Schwentner L, Wolters R, Koretz K, Wischnewsky MB, et al. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival-a retrospective multi-centre cohort study. Breast Cancer Res Treat 2012; 132:1073–1080. View Full Text | PubMed | CrossRef

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, et al. Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012; 8:403–414.

Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, et al. Prevalence and Prognostic Role of Triple-Negative Breast Cancer by Race: A Surveillance Study. Clin Breast Cancer 2011; 11:332–341. View Full Text | PubMed | CrossRef

Tchou J, Wang LC, Selven B, Zhang HT, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012; 133:799–804. View Full Text | PubMed | CrossRef

Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011; 22:2234–2240. View Full Text | PubMed | CrossRef

Whitfield R, Kollias J, De Silva P, Zorbas H, et al. Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit. ANZ Journal of Surgery 2012; 82:234–239. View Full Text | PubMed | CrossRef

Wu JN, Li SR, Jia WJ, Su FX. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137:1505–1510. PubMed | CrossRef

Back to Top | Article Outline
Advances in the treatment of luminal breast cancer

Review: (pp. 49–54)

▪▪. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012; 30:2718–2724. [34]

Barrios C, Forbes JF, Jonat W, Conte P, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012; 23:1378–1386.

▪▪. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520–529. [38]

▪. Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor positive postmenopausal breast cancer. J Clin Oncol 2012; 30:1919–1925. [28]

Bouvard B, Hoppe E, Soulie P, Georgin-Mege M, et al. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol 2012; 23:1151–1155. View Full Text | PubMed | CrossRef

Coates AS, Colleoni M, Goldhirsch A. Is adjuvant chemotherapy useful for women with luminal a breast cancer? J Clin Oncol 2012; 30:1260–1263.

Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, et al. Outcome of special types of luminal breast cancer. Ann Oncol 2012; 23:1428. View Full Text | PubMed | CrossRef

Cottu P, Marangoni E, Assayag F, de Cremoux P, et al. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 2012; 133:595–606. View Full Text | PubMed | CrossRef

▪. Curtis C, Shah SP, Chin S, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486:346–352. [22]

Dawood S, Shaikh AJ, Buchholz TA, Cortes J, et al. The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 2012; 118:2780–2786. View Full Text | PubMed | CrossRef

Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, et al. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol 2012; 23:1138–1144. View Full Text | PubMed | CrossRef

▪. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353–360. [23]

Goncalves A. PARP inhibitors and breast cancer: update and perspectives. Bull Cancer 2012; 99:441–451. PubMed

Hille U, Soergel P, Langer F, Schippert C, et al. Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients. Breast J 2012; 18:145–150. View Full Text | PubMed | CrossRef

▪. Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012; 30:729–734. [08]

Kim HJ, Lee YM, Ko BS, Lee JW, et al. Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer. Ann Surg Oncol 2011; 18:1830–1836.

Kong FL, Kim EE, Yang DJ. Targeted Nuclear Imaging of Breast Cancer: Status of Radiotracer Development and Clinical Applications. Cancer Biother Radiopharm 2012; 27:105–112. PubMed | CrossRef

Lundin KB, Henningson M, Hietala M, Ingvar C, et al. Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. Br J Cancer 2011; 105:1676–1683. PubMed | CrossRef

▪. Mamounas EP, Tang G, Paik S, et al. Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: results from NSAB B-28. J Clin Oncol 2012; 30 (suppl 27):abstr 1. [16]

▪. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367:435–444. [27]

Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 2011; 17:2874–2884. PubMed

Retrouvey H. Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer (vol 17, pg 2874, 2011). Clin Cancer Res 2011; 17:6952. PubMed

▪▪. Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012; 136:503–511. [25]

Samarnthai N, Elledge R, Prihoda TJ, Huang J, et al. Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy. Breast J 2012; 18:362–366. View Full Text | PubMed | CrossRef

▪. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400–404. [24]

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, et al. Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012; 8:403–414.

Takei H, Ohsumi S, Shimozuma K, Takehara M, et al. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04). Breast Cancer Res Treat 2012; 133:227–236.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, et al. Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Res Treat 2012; 134:245–251. View Full Text | PubMed | CrossRef

Tokuda E, Seino Y, Arakawa A, Saito M, et al. Estrogen receptor-alpha directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2012; 133:427–436. View Full Text | PubMed | CrossRef

Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 2011; 13:221. PubMed | CrossRef

Whitfield R, Kollias J, De Silva P, Zorbas H, et al. Use of trastuzumab in Australia and New Zealand: results from the National Breast Cancer Audit. ANZ Journal of Surgery 2012; 82:234–239. View Full Text | PubMed | CrossRef

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 2012; 133:367–373. View Full Text | PubMed | CrossRef

Yamamoto D, Iwase S, Yoshida H, Kuroda Y, et al. Efficacy of Meloxicam in Combination with Preoperative Chemotherapy for Breast Cancer - Japan Breast Cancer Research Network (JBCRN) 02-1 Trial. Anticancer Res 2011; 31:3567–3571. PubMed

Yang XHR, Figueroa JD, Falk RT, Zhang H, et al. Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers - art. no. R64. Breast Cancer Res 2012; 14:R64. PubMed | CrossRef

Back to Top | Article Outline
Emerging strategies for the dual inhibition of HER2-positive breast cancer

Review: (pp. 55–65)

Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012; 131:371–383. View Full Text | PubMed | CrossRef

Azim HA. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncol 2012; 8:135–144. View Full Text | PubMed | CrossRef

Azim HA, Azim HA. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncol 2012; 8:135–144. View Full Text | PubMed | CrossRef

Baek J-M, Jin Q, Ensor J, Boulbes DR, et al. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer. Breast Cancer Res Treat 2011; 130:1029–1036.

▪. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379:633–640. [36]

▪▪. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109–119. [48]

Bayraktar S, Gonzalez-Angulo AM, Lei XD, Buzdar AU, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012; 118:2385–2393. PubMed | CrossRef

Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 2011; 130:145–153. View Full Text | PubMed | CrossRef

Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118:1202–1211. PubMed | CrossRef

▪▪. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30:2585–2592. [35]

Brufsky AM, Mayer M, Rugo HS, Kaufman PA, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17:4834–4843.

Burris HA. 3rdRugo HS, Vukelja SJ, Vogel CL, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398–405. PubMed | CrossRef

Rugo HS, Vukelja SJ, Vogel CL, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398–405.

Chan A, McGregor SR. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab. Intern Med J 2012; 42:267–274. View Full Text | PubMed | CrossRef

Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, et al. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 2012; 23:1788–1795. View Full Text | PubMed | CrossRef

D'Huyvetter M, Aerts A, Xavier C, Vaneycken I, et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging 2012; 7:254–264.

Dawood S, Shaikh AJ, Buchholz TA, Cortes J, et al. The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 2012; 118:2780–2786. View Full Text | PubMed | CrossRef

Fleeman N, Bagust A, Boland A, Dickson R, et al. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess 2011; 15:1–93iii-iv.

Frati A, Chereau E, Coutant C, Bezu C, et al. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. Breast Cancer Res Treat 2012; 132:601–607. View Full Text | PubMed | CrossRef

Giordano A, Giuliano M, De Laurentiis M, Arpino G, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23:1144–1150. View Full Text | PubMed | CrossRef

Gori S, Montemurro F, Spazzapan S, Metro G, et al. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 2012; 23:1436. View Full Text | PubMed | CrossRef

He X, Esteva FJ, Ensor J, Hortobagyi GN, et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+breast cancer. Ann Oncol 2012; 23:1771–1780. View Full Text | PubMed | CrossRef

Horiguchi J, Oyama T, Takata D, Rokutanda N, et al. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Anticancer Res 2011; 31:3041–3046. PubMed

▪▪. Hurvitz S, Dirix L, Kocsis J, et al. Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H + T) in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study. Eur J Cancer 2011; 47 (S330):abstract 5001. [56]

Jelovac D, Wolff AC. The Adjuvant Treatment of HER2-Positive Breast Cancer. Curr Treat Options Oncol 2012; 13:230–239. PubMed | CrossRef

Joerger M, Thurlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol 2011; 22:17–23.

Keating GM. Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer. Drugs 2012; 72:353–360.

Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, et al. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 2011; 22:2387–2393.

Kiess AP, McArthur HL, Mahoney K, Patil S, et al. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 2012; 118:1982–1988.

Kong FL, Kim EE, Yang DJ. Targeted Nuclear Imaging of Breast Cancer: Status of Radiotracer Development and Clinical Applications. Cancer Biother Radiopharm 2012; 27: 105–112. PubMed | CrossRef

La Bonte MJ, Wilson PM, Yang D, Zhang W, et al. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol 2012; 23:1455–1464. View Full Text | PubMed | CrossRef

Lips EH, Mulder L, de Ronde JJ, Mandjes IAM, et al. Neoadjuvant chemotherapy in ER+HER2-breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012; 131:827–836. View Full Text | PubMed | CrossRef

Lipton A, Leitzel K, Ali SM, Carney W, et al. Human Epidermal Growth Factor Receptor 2 (HER2) Extracellular Domain Levels Are Associated with Progression-Free Survival in Patients with HER2-Positive Metastatic Breast Cancer Receiving Lapatinib Monotherapy. Cancer 2011; 117: 5013–5020. PubMed | CrossRef

Livingston RB, Barlow WE, Kash JJ, Albain KS, et al. SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat 2011; 130:123–131. View Full Text | PubMed | CrossRef

Llombart-Cussac A, Guerrero A, Galan A, Caranana V, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 2012; 14:125–131. PubMed

Lopes N, Carvalho J, Duraes C, Sousa B, et al. 1Alpha,25-dihydroxyvitamin D-3 Induces de novo E-cadherin Expression in Triple-negative Breast Cancer Cells by CDH1-promoter Demethylation. Anticancer Res 2012; 32:249–257.

Lubig J, Lattrich C, Springwald A, Haring J, et al. Effects of a Combined Treatment With GPR30 Agonist G-1 and Herceptin on Growth and Gene Expression of Human Breast Cancer Cell Lines. Cancer Invest 2012; 30:372–379. PubMed | CrossRef

Martin M, Sanchez-Rovira P, Munoz M, Baena-Canada JM, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 2011; 22:2591–2596. View Full Text | PubMed | CrossRef

Mayer EL, Baurain J-F, Sparano J, Strauss L, et al. A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res 2011; 17:6897–6904.

McArthur HL, Mahoney KM, Morris PG, Patil S, et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 2011; 117:5461–5468. PubMed | CrossRef

Metro G, Foglietta J, Russillo M, Stocchi L, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22:625–630. View Full Text | PubMed | CrossRef

Mittendorf EA, Clifton GT, Holmes JP, Clive KS, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118:2594–2602. View Full Text | PubMed | CrossRef

Mizuta N, Nishiyama A, Mizuta M, Goto M, et al. [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer]. Gan To Kagaku Ryoho 2011; 38:1491–1494. PubMed

Modi S, Stopeck A, Linden H, Solit D, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17:5132–5139.

Montemurro F, Rossi V, Cossu Rocca M, Martinello R, et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012; 118:17–26.

Montemurro F, Rossi V, Rocca MC, Martinello R, et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012; 118:17–26.

Moon YW, Park S, Sohn JH, Kang DR, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol 2011; 137:1123–1130. PubMed | CrossRef

Nakamura S, Ando M, Masuda N, Aogi K, et al. Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer. Clin Breast Cancer 2012; 12:49–56. View Full Text | PubMed | CrossRef

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, et al. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 2012; 134:419–428. View Full Text | PubMed | CrossRef

Olson EM, Lin NU, Di Piro PJ, Najita JS, et al. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol 2012; 23:93–97. View Full Text | PubMed | CrossRef

Onitilo AA, Engel JM, Stankowski RV, Liang H, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2012; 134:291–298. View Full Text | PubMed | CrossRef

Pachmann K, Camara O, Kroll T, Gajda M, et al. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as ‘‘Liquid Biopsy’': trastuzumab in HER2/neu-positive breast carcinoma. J Cancer Res Clin Oncol 2011; 137:1317–1327. PubMed | CrossRef

Park YH, Im SA, Cho EY, Choi YL, et al. Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy? Breast Cancer Res Treat 2012; 133:247–255.

Peron J, Tredan O, Ray-Coquard I, Bachelot T, et al. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. Bull Cancer 2012; 99: E18–25. PubMed

Peron J, Tredan O, Ray-Coquard I, Bachelot T, et al. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. Bull Cancer 2012; 99:E18–E25. PubMed

Pestrin M, Bessi S, Puglisi F, Minisini AM, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 2012; 134:283–289. View Full Text | PubMed | CrossRef

Prabhu R, Godette K, Carlson G, Losken A, et al. The Impact of Skin-Sparing Mastectomy With Immediate Reconstruction in Patients With Stage III Breast Cancer Treated With Neoadjuvant Chemotherapy and Postmastectomy Radiation. Int J Radiat Oncol Biol Phys 2012; 82:E587–E593. PubMed | CrossRef

▪. Press MF, Sauter G, Buyse M, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol 2011; 29:859–867. [22]

Rastogi P, Buyse ME, Swain SM, Jacobs SA, et al. Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2(-) Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group. Clin Breast Cancer 2011; 11:228–234. View Full Text | PubMed | CrossRef

Rhee J, Han S-W, Cha Y, Ham HS, et al. High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Res Treat 2011; 125:107–114. View Full Text | PubMed | CrossRef

▪▪. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSAB B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30:3792–3799. [13]

Rugo HS, Chien AJ, Franco SX, Stopeck AT, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2012; 134:13–20.

Sachdev JC, Jahanzeb M. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Clin Breast Cancer 2012; 12:19–29. View Full Text | PubMed | CrossRef

Semiglazov V, Eiermann W, Zambetti M, Manikhas A, et al. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Ejso 2011; 37:856–863.

▪▪. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273–1283. [08]

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, et al. Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012; 8:403–414.

Tahover E, Sonnenblick A, Peretz T, Katz D. [Update: adjuvant trastuzumab in HER2 positive breast cancer]. Harefuah 2012; 151:37–4261. PubMed

Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011; 22:1302–1307. View Full Text | PubMed | CrossRef

Tan WW, Allred JB, Salim M, Flynn P, et al. Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial. Clin Breast Cancer 2012; 12:81–86. PubMed | CrossRef

Torrisi R, Bagnardi V, Rotmensz N, Scarano E, et al. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat 2011; 126:431–441. View Full Text | PubMed | CrossRef

Tsang RY, Finn RS. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 2012; 106:6–13. PubMed | CrossRef

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 2011; 130:29–40. View Full Text | PubMed | CrossRef

van Nes JGH, de Kruijf EM, Putter H, Faratian D, et al. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat 2012; 133:49–59.

▪▪. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783–1791. [55]

von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47:2273–2281.

von Minckwitz G, Schweller K, Schmidt M, Barinoff J, et al. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47:2273–2281.

▪▪. Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796–1804. [69]

Webster RM, Abraham J, Palaniappan N, Caley A, et al. Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? Br J Cancer 2012; 106:32–38.

Back to Top | Article Outline
Update on neoadjuvant/preoperative therapy of breast cancer: experiences from the German Breast Group

Review: (pp. 66–73)

Aft RL, Naughton M, Trinkaus K, Weilbaecher K. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer 2012; 107:7–11. PubMed | CrossRef

Bayraktar S, Arun B. Dose-Dense Chemotherapy for Breast Cancer. Breast J 2012; 18:261–266. View Full Text | PubMed | CrossRef

Bourgier C, Calvo FA, Marsiglia H, Martin M. Overview of preoperative radiochemotherapy in breast cancer: past or future? Clin Transl Oncol 2011; 13:446–450.

Dellapasqua S, Mazza M, Rosa D, Ghisini R, et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 2011; 20:319–323. PubMed | CrossRef

Dittrich C, Solska E, Manikhas A, Eniu A, et al. A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer. Cancer Invest 2012; 30:309–316. PubMed | CrossRef

Dong NN, Wang MY, Li HQ, Cui YC, et al. Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2012; 69:1315–1322.

Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol 2012; 23:597. View Full Text | PubMed | CrossRef

Gatek J, Vrana D, Hnatek L, Bakala J, et al. Sentinel node biopsy and neoadjuvant chemotherapy in the treatment of breast cancer. J 2012; 17:265–270.

▪▪. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377–384. [06]

▪. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:25–32. [08]

Goldhirsch A, Wood WC, Coates AS, Gelber RD, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22:1736–1747.

Guarneri V, Pecchi A, Piacentini F, Barbieri E, et al. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer. Ann Surg Oncol 2011; 18:2150–2157. PubMed | CrossRef

Hartog H, Horlings HM, van der Vegt B, Kreike B, et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat 2011; 129:725–736. View Full Text | PubMed | CrossRef

Hille U, Soergel P, Langer F, Schippert C, et al. Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients. Breast J 2012; 18:145–150. View Full Text | PubMed | CrossRef

Hirsh RL, De Michele A. The Role of Lapatinib in the Preoperative Therapy of Breast Cancer. Curr Oncol Rep 2012; 14:44–47. PubMed | CrossRef

Ibrahim NA, Oludara MA. Socio-demographic factors and reasons associated with delay in breast cancer presentation: A study in Nigerian women. Breast 2012; 21:416–418. PubMed | CrossRef

Jassem J, Fein L, Karwal M, Campone M, et al. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies. Breast 2012; 21:89–94. PubMed | CrossRef

Karachaliou N, Kouroussis C, Papakotoulas P, Kalbakis K, et al. A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 2012; 69:1345–1352. PubMed | CrossRef

Kim KP, Ahn JH, Kim SB, Jung KH, et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol 2012; 69:1221–1227. PubMed | CrossRef

Kim SR, Paik S. Genomics of Adjuvant Therapy for Breast Cancer. Cancer J 2011; 17:500–504. View Full Text | PubMed | CrossRef

Le Tourneau C, Dettwiler S, Beuzeboc P, Alran S, et al. Pathologic Response to Short Intensified Taxane-free Neoadjuvant Chemotherapy in Patients with Highly Proliferative Operable Breast Cancer. Am J Clin Oncol-Cancer Clin Trials 2012; 35:242–246. View Full Text | PubMed | CrossRef

Lin C, Chen DR, Chang KJ, Chang TW, et al. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers. Cancer Chemother Pharmacol 2012; 69:1363–1368. PubMed | CrossRef

Lombardi G, Nicoletto MO, Gusella M, Fiduccia P, et al. Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. Cancer Chemother Pharmacol 2012; 69:781–787. PubMed | CrossRef

Mohammadianpanah M, Ashouri Y, Hoseini S, Amadloo N, et al. The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial. Breast Cancer Res Treat 2012; 132:853–861. View Full Text | PubMed | CrossRef

Moreno-Aspitia A. Neoadjuvant therapy in early-stage breast cancer. Crit Rev Oncol/Hematol 2012; 82: 187–199.

Nakai K, Mitomi H, Alkam Y, Arakawa A, et al. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. Cancer Chemother Pharmacol 2012; 69:923–930. PubMed | CrossRef

Nakayama T, Morita S, Takashima T, Kamigaki S, et al. Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. Anticancer Res 2011; 31:3035–3039. PubMed

Palta M, Yoo S, Adamson JD, Prosnitz LR, et al. Preoperative single fraction partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2012; 82:37–42. PubMed | CrossRef

Samarnthai N, Elledge R, Prihoda TJ, Huang J, et al. Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy. Breast J 2012; 18:362–366. View Full Text | PubMed | CrossRef

Untch M, Fasching PA, Konecny GE, von Koch F, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary breast cancer–results at the time of surgery. Ann Oncol 2011; 22:1988–1998.

Untch M, von Minckwitz G, Konecny GE, Conrad U, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer-outcome on prognosis. Ann Oncol 2011; 22:1999–2006. View Full Text | PubMed | CrossRef

van Nes JGH, Fontein DBY, Hille ETM, Voskuil DW, et al. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 2012; 134:267–276. View Full Text | PubMed | CrossRef

Vici P, Brandi M, Giotta F, Foggi P, et al. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Ann Oncol 2012; 23:1121–1129. View Full Text | PubMed | CrossRef

Vilar VS, Goldman SM, Ricci MD, Pincerato K, et al. Analysis by MRI of Residual Tumor After Radiofrequency Ablation for Early Stage Breast Cancer. American Journal of Roentgenology 2012; 198:W285–W291. PubMed | CrossRef

▪▪. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796–1804. [01]

von Minckwitz G, Untch M, Nuesch E, Loibl S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125:145–156. View Full Text | PubMed | CrossRef

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat 2012; 133:367–373. View Full Text | PubMed | CrossRef

Yuan P, Xu BH, Wang JY, Ma F, et al. Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy. Chin Med J 2012; 125:775–779. View Full Text | PubMed

Back to Top | Article Outline
Update on breast cancer surgery approaches

Review: (pp. 74–80)

Adkisson CD, Vallow LA, Kowalchik K, McNeil R, et al. Patient age and preoperative breast MRI in women with breast cancer: biopsy and surgical implications. Ann Surg Oncol 2011; 18:1678–1683. View Full Text | PubMed | CrossRef

Aufforth R, Jain J, Morreale J, Baumgarten R, et al. Paravertebral blocks in breast cancer surgery: is there a difference in postoperative pain, nausea, and vomiting? Ann Surg Oncol 2012; 19:548–552.

Bergmann A, Mendes VV, de Almeida Dias R, do Amaral E, Silva B, et al. Incidence and risk factors for axillary web syndrome after breast cancer surgery. Breast Cancer Res Treat 2012; 131:987–992. View Full Text | PubMed | CrossRef

Bergmann A, Mendes VV, Dias RD, Silva BDE, et al. Incidence and risk factors for axillary web syndrome after breast cancer surgery. Breast Cancer Res Treat 2012; 131: 987–992. View Full Text | PubMed | CrossRef

Boccardo FM, Casabona F, Friedman D, Puglisi M, et al. Surgical prevention of arm lymphedema after breast cancer treatment. Ann Surg Oncol 2011; 18:2500–2505. PubMed | CrossRef

Bunn F, Jones DJ, Bell-Syer S. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery - art. no. CD005360. Cochrane Database Syst Rev 2012;5360.

Caldon LJM, Collins KA, Reed MW, Sivell S, et al. Clinicians' concerns about decision support interventions for patients facing breast cancer surgery options: understanding the challenge of implementing shared decision-making. Health Expect 2011; 14:133–146. View Full Text | PubMed | CrossRef

Chatzidaki P, Mellos C, Briese V, Mylonas I. Perioperative complications of breast cancer surgery in elderly women (≥80 years). Ann Surg Oncol 2011; 18:923–931. View Full Text | PubMed | CrossRef

Collins KK, Liu Y, Schootman M, Aft R, et al. Effects of breast cancer surgery and surgical side effects on body image over time. Breast Cancer Res Treat 2011; 126:167–176. View Full Text | PubMed | CrossRef

▪▪. Darby S, McGale P, Correa C, et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011; 378:1707–1716. [64]

Daroui P, Gabel M, Khan AJ, Haffty BG, et al. Utilization of Breast Conserving Therapy in Stages 0, I, and II Breast Cancer Patients in New Jersey An American College of Surgeons National Cancer Data Base (NCDB) Analysis. Am J Clin Oncol-Cancer Clin Trials 2012; 35:130–135. View Full Text | PubMed | CrossRef

Denewer A, Farouk O, Kotb S, Setit A, et al. Quality of life among Egyptian women with breast cancer after sparing mastectomy and immediate autologous breast reconstruction: a comparative study. Breast Cancer Res Treat 2012; 133:537–544. View Full Text | PubMed | CrossRef

Freeman AB, Huang B, Dragun AE. Patterns of Care With Regard to Surgical Choice and Application of Adjuvant Radiation Therapy for Preinvasive and Early Stage Breast Cancer in Rural Appalachia. Am J Clin Oncol-Cancer Clin Trials 2012; 35:358–363. View Full Text | PubMed | CrossRef

▪. Gainer SM, Lucci A. Oncoplastics: techniques for reconstruction of partial breast defects based on tumor location. J Surg Oncol 2011; 103:341–347. [58]

Garcia-Etienne CA, Forcellini D, Sagona A, Caviggioli F, et al. Breast reconstruction: A quality measure for breast cancer care? Breast 2012; 21:105–106.

▪▪. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569–575. [82]

Gogas H, Dafni U, Karina M, Papadimitriou C, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat 2012; 132:609–619. View Full Text | PubMed | CrossRef

Grady I, Gorsuch-Rafferty H, Hadley P. Preoperative Staging with Magnetic Resonance Imaging, with Confirmatory Biopsy, Improves Surgical Outcomes in Women with Breast Cancer without Increasing Rates of Mastectomy. Breast J 2012; 18:214–218. View Full Text | PubMed | CrossRef

Gravgaard KH, Lyng MB, Laenkholm AV, Sokilde R, et al. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer. Breast Cancer Res Treat 2012; 134:207–217. View Full Text | PubMed | CrossRef

Hogan BV, Peter MB, Achuthan R, Beaumont AJ, et al. Perioperative reductions in circulating lymphocyte levels predict wound complications after excisional breast cancer surgery. Ann Surg 2011; 253:360–364. View Full Text | PubMed | CrossRef

Mislowsky A, Domchek S, Stroede C, Bergey MR, et al. Breast cancer surgery trend changes since the introduction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mutation carriers treated at a single institution. Ann Surg Oncol 2011; 18:745–751. View Full Text | PubMed | CrossRef

Moore W. Extreme measures: the history of breast cancer surgery. Bmj 2012; 344:e834. View Full Text | PubMed | CrossRef

Moore W. PAST CARING Extreme measures: the history of breast cancer surgery - art. no. e834. Br Med J 2012; 344:8.

Morrow M, Katz SJ. The challenge of developing quality measures for breast cancer surgery. JAMA-J Am Med Assoc 2012; 307:509–510. View Full Text | PubMed | CrossRef

Munhoz AM, Gemperli R, Filassi JR. Effects of breast cancer surgery and surgical side effects on body image over time. Breast Cancer Res Treat 2011; 126:261–262author reply 263–264.

Park SH, Kim MJ, Park B-W, Moon HJ, et al. Impact of preoperative ultrasonography and fine-needle aspiration of axillary lymph nodes on surgical management of primary breast cancer. Ann Surg Oncol 2011; 18:738–744. View Full Text | PubMed | CrossRef

Peltoniemi P, Peltola M, Hakulinen T, Hakkinen U, et al. The effect of hospital volume on the outcome of breast cancer surgery. Ann Surg Oncol 2011; 18:1684–1690. View Full Text | PubMed | CrossRef

Riezebos PM, Snoeck MM, Kleine Koerkamp HJ, Strobbe LJ. A field block for breast cancer surgery: technical aspects and a pilot study. Breast J 2011; 17:550–552. View Full Text | PubMed | CrossRef

Riezebos PM, Snoeck MM, Koerkamp HJK, Strobbe LJ. A Field Block for Breast Cancer Surgery: Technical Aspects and a Pilot Study. Breast J 2011; 17:550–552. View Full Text | PubMed | CrossRef

Santanelli F, Paolini G, Longo B. Comments on: Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery (Clough KB, Kaufman GJ,, et al. ASO DOI 10.1245/s10434-009-0792-y). Ann Surg Oncol 2011; 18:Suppl 3S257–S258author reply S259–260.

▪▪. Smith GL, Xu Y, Buchholz TA, et al. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA 2012; 307:1827–1837. [71]

▪. Tausch C, Steger GG, Haid A, et al. Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14. Breast J 2011; 17:230–238. [88]

Walcott BP, Cvetanovich GL, Barnard ZR, Nahed BV, et al. Surgical treatment and outcomes of metastatic breast cancer to the spine. J Clin Neurosci 2011; 18:1336–1339. PubMed | CrossRef

Zhang Z-T, Zhang H-W, Fang X-D, Wang L-M, et al. Cosmetic outcome and surgical site infection rates of antibacterial absorbable (Polyglactin 910) suture compared to Chinese silk suture in breast cancer surgery: a randomized pilot research. Chin Med J 2011; 124:719–724. View Full Text | PubMed

© 2013 Lippincott Williams & Wilkins, Inc.

Login